Search Results

You are looking at 31 - 40 of 576 items for :

  • Refine by Access: All x
Clear All
Full access

Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial

Romy M. van Amelsfoort, Iris Walraven, Jacobien Kieffer, Edwin P.M. Jansen, Annemieke Cats, Nicole C.T. van Grieken, Elma Meershoek-Klein Kranenbarg, Hein Putter, Johanna W. van Sandick, Karolina Sikorska, Cornelis J.H. van de Velde, Neil K. Aaronson, Marcel Verheij, and on behalf of the CRITICS Investigators

functioning, role functioning, cognitive functioning, emotional functioning, and social functioning), 3 multi-item symptom scales (fatigue, nausea and vomiting, and pain), 6 single-item symptom scales (dyspnea, insomnia, appetite loss, constipation, diarrhea

Full access

Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis

Tara M. Mackay, Anouk E.J. Latenstein, Mirjam A.G. Sprangers, Lydia G. van der Geest, Geert-Jan Creemers, Susan van Dieren, Jan-Willem B. de Groot, Bas Groot Koerkamp, Ignace H. de Hingh, Marjolein Y.V. Homs, Evelien J.M. de Jong, I. Quintus Molenaar, Gijs A. Patijn, Lonneke V. van de Poll-Franse, Hjalmar C. van Santvoort, Judith de Vos-Geelen, Johanna W. Wilmink, Casper H. van Eijck, Marc G. Besselink, Hanneke W.M. van Laarhoven, and for the Dutch Pancreatic Cancer Group

cancer-specific EORTC QLQ-C30 questionnaire encompasses global health status, 5 functioning scales (ie, physical, role, emotional, cognitive, and social functioning) and 8 symptom scales/items (ie, fatigue, nausea and vomiting, pain, dyspnea, insomnia

Full access

Survivorship: Sleep Disorders, Version 1.2014

Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Muhammad Raza, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole McMillian, and Deborah Freedman-Cass

parasomnias. 1 Sleep disorders affect 30% to 50% of patients with cancer and survivors, often in combination with fatigue, anxiety, or depression. 1 - 10 Improvements in sleep lead to improvements in fatigue, mood, and quality of life. 11 Most clinicians

Full access

NCCN Guidelines® Insights: Survivorship, Version 1.2023

Featured Updates to the NCCN Guidelines

Tara Sanft, Andrew Day, Shannon Ansbaugh, Saro Armenian, K. Scott Baker, Tara Ballinger, Wendy Demark-Wahnefried, Kristin Dickinson, Nathan Paul Fairman, Josephine Felciano, Tessa Faye Flores, Debra L. Friedman, Nicolette M. Gabel, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Divya Koura, Kimberly Lee, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C.F. Moore, Natalie Moryl, Heather Neuman, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, Andrea Porpiglia, M. Alma Rodriguez, Lidia Schapira, Anna L. Schwartz, Sophia Smith, Amye Tevaarwerk, Eric Yang, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

, and this number is projected to surpass 22 million by 2030. 1 , 2 Unfortunately, a considerable number of survivors experience late and/or long-term physical and/or psychosocial effects of cancer and its treatment. 3 – 5 Sleep disturbances, fatigue

Full access

Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors

Christina Teng, Venkatesha, Prunella L. Blinman, and Janette L. Vardy

discontinuation of oxaliplatin. Abbreviation: PN, peripheral neuropathy. a Nausea (n=1), fatigue (n=1), vomiting (n=1), bleeding (n=1), thrombophlebitis (n=1), de-escalated due to clinical trial (n=2). Burden of PN Single Item Score of Numbness and

Full access

CLO19-059: A Systematic Review and Meta- Analysis of Randomized Controlled Trials to Evaluate the Risk of Health-Related Quality of Life Events in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated With CDK 4/6 Inhibitors

Rachana Yendala, Kyaw Thein, Sriman Swarup, Anita Sultan, Somedeb Ball, Miguel Quirch, Myo H. Zaw, Yin M. Myat, and Catherine Jones

Background: Pain, fatigue, hot flushes, and rash significantly contribute to quality of life in breast cancer patients undergoing chemotherapy. Hormone receptor-positive breast cancer is a common entity among women worldwide. In cancer cells, CDK4

Full access

CLO19-050: Risk of Health- Related Quality of Life (HRQOL) Events in Patients With Advanced Solid Tumors Treated With Cabozantinib: A Combined Analysis of Four Phase 3 Randomized Controlled Trials

Sriman Swarup, Anita Sultan, Nusrat Jahan, Upama Sharma, Nimesh Adhikari, Yin M. Myat, Ye Aung, Myo H. Zaw, and Kyaw Z. Thein

treated with cabozantinib. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases, and meeting abstracts through September 30, 2018. Phase 3 trials that mention HRQOL events like pain, arthralgia, fatigue

Full access

Integrating Palliative Care Into Comprehensive Cancer Care

Janet L. Abrahm

also core palliative care skills, as are self-care and prevention of compassion fatigue (see later discussion). Finally, fellows should know when to consult a psychiatrist or palliative care expert. As Von Roenn and Temel 34 recommend, “When the

Full access

HSR19-109: The Healthy Days Measure in a Metastatic Castration-Resistant Prostate Cancer Population Treated With Novel Oral Therapies

Neil M. Schultz, Eleanor O. Caplan, Sam Wilson, Richard Sheer, and Brandon T. Suehs

Therapy-Fatigue (FACIT-Fatigue). Higher scores indicated higher HRQoL on all surveys, except the HDs scale, where higher numbers indicated lower HRQoL (ie, unhealthy days). Pearson correlations with SF-36 and HDs measures and SCA and FACIT-Fatigue were

Full access

EPR19-071: Risk of Hematologic Toxicities and Health-Related Quality of Life Events in Patients With Hematologic Malignancies Treated With Ibrutinib: A Combined Analysis of 6 Phase III Trials

Miguel Quirch, Sriman Swarup, Anita Sultan, Wai L. Thein, Zayar M. Oo, Nyein H. Yu, Myo H. Zaw, Donald P. Quick, and Kyaw Z. Thein

.565–1.168; P =.261); neutropenia, 0.956 (95% CI: 0.720–1.268; P =.754); thrombocytopenia, 1.054 (95% CI: 0.450–2.470; P =.904); fatigue, 0.896 (95% CI: 0.761–1.056; P =.192); pyrexia, 1.123 (95% CI: 0.893–1.413; P =.322); and arthralgia, 1.863 (95% CI: 1